Exogenous VEGF-C augments the efficacy of therapeutic lymphangiogenesis induced by allogenic bone marrow stromal cells in a rabbit model of limb secondary lymphedema

Japanese Journal of Clinical Oncology

Volumn 41, Issue 7, 2011, Pages 841-846

  Zhou, Hua ^a   Wang, Mo ^a   Hou, Chuanqiang ^a   Jin, Xing ^a   Wu, Xuejun ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Bone marrow stromal cells; Lymphedema; Transplantation; VEGF C

Indexed keywords

BETA1 INTEGRIN; CD11B ANTIGEN; CD45 ANTIGEN; HERMES ANTIGEN; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL RABBIT; FEMALE; IMMUNOHISTOCHEMISTRY; LEG EDEMA; LYMPH VESSEL; LYMPHANGIOGENESIS; LYMPHEDEMA; MALE; NONHUMAN; PERIPHERAL EDEMA; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; VOLUMETRY; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; FEASIBILITY STUDIES; HINDLIMB; IMMUNOHISTOCHEMISTRY; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; LYMPHEDEMA; RABBITS; TRANSPLANTATION, HOMOLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 79960060334     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr055     Document Type: Article

References (16)

1. Fang Y. The construction of human lymphatic vessels by mesenchymal stem cells in vitro (dissertation). Shandong University 2007.
2. Karkkainen MJ, Saaristo A, Jussila L, Karila KA, Lawrence EC, Pajusola K, et al. A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci USA 2001;98:12677-82.
3. Hou C, Wu X, Jin X. Autologous bone marrow stromal cells transplantation for the treatment of secondary arm lymphedema: a prospective controlled tudy in patients with breast cancer related lymphedema. Jpn J Clin Oncol 2008;38:670-4.
4. Tang J, Xie Q, Pan G, Wang J, Wang M. Mesenchymal stem cells participate in angiogenesis and improve heart function in rat model of myocardial schemia with reperfusion. Eur J Cardiothorac Surg 2006;30:353-61.
5. Chedrawy EG, Wang JS, Nguyen DM, Shum-Tim D, Chiu RC. Incorporation and integration of implanted myogenic and stem cells into native yocardial fibers: anatomic basis for functional improvements. J Thorac Cardiovasc Surg 2002;124:584-90.
6. Lee-Donaldson L, Witte MH, Bernas M, Witte CL, Way D, Stea B. Refinement of a rodent model of peripheral lymphedema. Lymphology, 999;32:111-7.
7. Liu Y, Fang Y, Dong P, Gao J, Liu R, Tian H, et al. Effect of vascular endothelial growth factor C (VEGF-C) gene transfer in rat model of secondary lymphedema. Vasc Pharmacol 2008;48:150-6.
8. Wang XL, Fang JP, Tang RY, Chen XM. Different significance between intratumoral and peritumoral lymphatic vessel density in gastric cancer: a retrospective study of 123 cases. BMC Cancer 2010;10:299.
9. Vermeulen PB, Gasparini G, Fox SB, Colpaert C, Marson LP, Gion M, et al. Quantification of angiogenesis in solid human tumors: An international onsensus on the methodology and criteria of evaluation. Eur J Cancer 1996;32A:2474-84.
10. Zhang Q, Guo R, Lu Y, Zhao L, Zhou Q, Schwarz EM, et al. VEGF-C, a lymphatic growth factor, is a RANKL target gene in osteoclasts that enhances steoclastic bone resorption through an autocrine mechanism. J Biol Chem 2008;283:13491-99.
11. Krishnan J, Kirkin V, Steffen A, Hegen M, Weih D, Tomarev S, et al. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res 2003;63:713-22.
12. Szuba A, Skobe M, Karkkainen MJ, Shin WS, Beynet DP, Rockson NB, et al. Therapeutic lymphangiogenesis with human recombinant VEGF-C. FASEB J 2002;16:1985-7.
13. Cheung L, Han J, Beilhack A, Joshi S, Wilburn P, Dua A, et al. An experimental model for the study of lymphedema and its response to therapeutic lymphangiogenesis. BioDrugs 2006;20:363-70.
14. Jin da P, An A, Liu J, Nakamura K, Rockson SG. Therapeutic responses to exogenous VEGF-C administration in experimental lymphedema: mmunohistochemical and molecular characterization. Lymphat Res Biol 2009;7:47-57.
15. Conrad C, Niess H, Huss R, Huber S, von Luettichau I, Nelson PJ, et al. Multipotent mesenchymal stem cells acquire a lymphendothelial phenotype and nhance lymphatic regeneration in vivo. Circulation 2009;119:281-9.
16. Tocci A, Forte L. Mesenchymal stem cell: use and perspectives. Hematol J 2003;4:92-6.